FIELD: biotechnology.
SUBSTANCE: heterodimeric antibodies directed against PD-1 and CTLA-4 are disclosed. Also disclosed are nucleic acids and vectors coding said antibodies, including a host cell thereof and a method of producing a heterodimeric antibody according to the invention, involving culturing said host cell.
EFFECT: invention provides effective specific binding with two antigens, leading to blocking of immune checkpoints, activation of T-cells and anticancer activity.
7 cl, 264 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
| MONOVALENT ASYMMETRIC BISPECIFIC ANTIBODIES WITH TANDEM FAB | 2017 |
|
RU2780591C2 |
| DOSAGE REGIMENS FOR ANTIBODIES AGAINST TIM-3 AND THEIR USE | 2018 |
|
RU2804775C2 |
| DESIGNED IL-2-FC FUSION PROTEINS | 2018 |
|
RU2812283C2 |
| ANTIBODIES TO PD-1 | 2015 |
|
RU2715628C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
